-
公开(公告)号:US20140107189A1
公开(公告)日:2014-04-17
申请号:US14106988
申请日:2013-12-16
IPC分类号: C07K14/535 , C07K14/505
CPC分类号: A61K48/0066 , A61K9/1271 , A61K9/145 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/177 , A61K38/1816 , A61K38/1891 , A61K38/191 , A61K38/193 , A61K38/212 , A61K38/45 , A61K38/4846 , A61K47/543 , A61K48/0033 , A61K48/005 , A61K48/0075 , C07H21/02 , C07K14/005 , C07K14/435 , C07K14/43595 , C07K14/47 , C07K14/4705 , C07K14/4713 , C07K14/4723 , C07K14/4746 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/5418 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/705 , C07K14/745 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/40 , C12N9/0069 , C12N9/0091 , C12N9/1051 , C12N9/1241 , C12N9/16 , C12N9/2402 , C12N9/2445 , C12N9/6435 , C12N9/6437 , C12N9/644 , C12N9/6443 , C12N9/6451 , C12N9/88 , C12N9/93 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00 , C12P21/005 , C12Y113/12007 , C12Y116/03001 , C12Y207/07012 , C12Y304/21007 , C12Y304/21022 , C12Y304/21027 , C12Y403/02001 , C12Y603/02019 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , Y02A50/463 , Y02A50/491
摘要: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
摘要翻译: 本发明涉及用于制备,制造和治疗使用肿瘤学相关多核苷酸,肿瘤学相关的初级转录物和肿瘤相关的mmRNA分子的组合物和方法。
-
公开(公告)号:US20230364233A1
公开(公告)日:2023-11-16
申请号:US18028628
申请日:2021-09-28
IPC分类号: A61K39/00 , C12N5/0783 , C12N15/11 , C12N9/22 , C12N15/90
CPC分类号: A61K39/4611 , C12N5/0636 , C12N15/11 , C12N15/111 , C12N9/22 , C12N15/907 , A61K39/464429 , C12N2310/20 , C12N2800/80 , C12N2310/321 , C12N2310/315 , A61K2239/26
摘要: Provided herein are gRNA comprising a targeting domain that targets CD6, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD6 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
-